Arrowhead to Present at Noble Financial Sixth Annual Equity Conference
PASADENA, Calif., May 28, 2010 (BUSINESS WIRE) -- Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Noble Financial Sixth Annual Equity Conference at 10:30 a.m. EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida.
The presentation will be webcast - audio / video / PowerPoint - live, and available for viewing at www.arrowheadresearch.com under the "Investor Relations" section of the Company's website by selecting the "Presentations and Events," tab. An archive of the presentation will be available for 90 days.
Arrowhead recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SiverLight viewer (a free download from presentation link) to participate.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.
SOURCE: Arrowhead Research Corporation
CONTACT:
The Piacente Group Brandi Floberg 212-481-2050 ir@arrowres.com
Copyright Business Wire 2010
**********************************************************************
As of Monday, 05-24-2010 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 07-30-2009 for ARWR @ $0.48.
For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com
SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2010 Comtex News Network, Inc. All rights reserved.
-0-
KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Technology
Consumer Electronics
Hardware
Nanotechnology
Health
Biotechnology
Other Health
Other Science
Science
SUBJECT CODE: Conference
Trade Show
PASADENA, Calif., May 28, 2010 (BUSINESS WIRE) -- Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Noble Financial Sixth Annual Equity Conference at 10:30 a.m. EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida.
The presentation will be webcast - audio / video / PowerPoint - live, and available for viewing at www.arrowheadresearch.com under the "Investor Relations" section of the Company's website by selecting the "Presentations and Events," tab. An archive of the presentation will be available for 90 days.
Arrowhead recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SiverLight viewer (a free download from presentation link) to participate.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.
SOURCE: Arrowhead Research Corporation
CONTACT:
The Piacente Group Brandi Floberg 212-481-2050 ir@arrowres.com
Copyright Business Wire 2010
**********************************************************************
As of Monday, 05-24-2010 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 07-30-2009 for ARWR @ $0.48.
For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com
SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2010 Comtex News Network, Inc. All rights reserved.
-0-
KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Technology
Consumer Electronics
Hardware
Nanotechnology
Health
Biotechnology
Other Health
Other Science
Science
SUBJECT CODE: Conference
Trade Show
SIGN UP FOR $THE WAVE (WAVERIDER$) EMAIL
http://investorshub.advfn.com/boards/board.aspx?board_id=16203

Recent ARWR News
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 05/19/2026 08:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 11:05:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/12/2026 08:35:16 PM
- Wall Street's Cardiac Bet: Where Diagnostics Meet the Money • PR Newswire (US) • 05/12/2026 12:30:00 PM
- Wall Street's Cardiac Bet: Where Diagnostics Meet the Money • PR Newswire (Canada) • 05/12/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:27:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:02:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 10:44:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/23/2026 08:44:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 09:16:20 PM
- Anti-Aging Protein Research Takes a Step Forward with Cell Cloning • PR Newswire (Canada) • 03/24/2026 03:05:00 PM
- Anti-Aging Protein Research Takes a Step Forward with Cell Cloning • PR Newswire (US) • 03/24/2026 03:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:05:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 11:00:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:49:43 PM
- Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A • InvestorsHub NewsWire • 02/17/2026 02:00:00 PM
- Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/05/2026 09:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 09:05:15 PM
- Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 • PR Newswire (US) • 02/04/2026 11:15:00 PM
